Carl Zeiss Meditec AG

  • WKN: 531370
  • ISIN: DE0005313704
  • Land: Deutschland

Nachricht vom 19.04.2021 | 10:06

Carl Zeiss Meditec AG returns to significant revenue growth in second quarter 2020/21

Carl Zeiss Meditec AG / Key word(s): Half Year Results
Carl Zeiss Meditec AG returns to significant revenue growth in second quarter 2020/21

19-Apr-2021 / 10:06 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Carl Zeiss Meditec AG returns to significant revenue growth in second quarter 2020/21

Jena, April 19, 2021

Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of EUR 767.4 million in the first half of fiscal year 2020/21 (previous year: EUR 714.9 million). This corresponds to a revenue development of +7.3% vs. the past year (after adjustment for currency effects[1]: +10.5%). In the second quarter of FY 2020/21, revenue amounted to EUR 398.5 million (past year: EUR 345.3 million) - a growth rate of +15.4% (after adjustment for currency effects: +18.8%).

Earnings before interest and taxes (EBIT)[2] amounted to EUR 162.7 million in the first half of FY 2020/21 (past year: EUR 102.5 million). EBIT margin (EBIT / revenue) was 21.2% (past year 14.3%). In the second quarter of FY 2020/21, EBIT amounted to EUR 89.3 million (past year: EUR 45.7 million). EBIT margin was 22.4% (past year: 13.2%). EBIT benefitted in part from a favorable development of product mix as well as a continuing low level of sales and marketing expenses due to the COVID-19 pandemic, compared to the past year.

Earnings per share (EPS)[3] amounted to EUR 1.12 (past year: EUR 0.71) for the first half of FY 2020/21. In the second quarter, EPS amounted to EUR 0.60 (past year: EUR 0.28).

Full results for the first half 2020/21 will be published on May 10, 2021.

During the further course of FY 2020/21, the company expects an ongoing normalization of business development. This expectation is based on the assumption that there will be no renewed deterioration in the global pandemic situation.

Revenue is expected to reach around EUR 1.6 billion (past year: EUR 1,335.5 million) in FY 2020/21. EBIT margin for FY 2020/21 is projected to reach a level of approximately 20% (past year: 13.3%), with significant support from lower than usual sales and marketing expenses in the current year. The company's mid-term margin outlook remains unchanged: to generate an EBIT margin sustainably above the level of 18%.
 
 

 

Contact for investors and press
Sebastian Frericks
Head of Investor Relations
Carl Zeiss Meditec AG
Tel.: +49 3641 220-116
E-Mail: investors.meditec@zeiss.com

 

[1] Currency-adjusted revenue growth is determined by weighing sales in the comparative period with current instead of actual historical exchange rates.
[2] Earnings before interest and taxes (also operating profit, EBIT) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated in accordance with IFRS standards (see Annual Report 2019/20, p. 78 for reconciliation).
[3] Earnings per share (also EPS) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated according to IFRS standards (see Annual Report 2019/20, p. 78 for reconciliation).


19-Apr-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“

GBC-Fokusbox

Kaufen: Vectron Systems AG legt verstärkt Fokus auf Digitalgeschäft

Nachdem die Vectron Systems AG bislang insbesondere Kassensysteme verkauft hat, wird nun das Digitalgeschäft stärker in den Fokus rücken. Damit sollen die wiederkehrenden Einnahmen und die Wertschöpfung je Kunde deutlich erhöht werden. Über Cloud-Module können die Kunden nun mehrere digitale Services, die sie sonst über viele Einzelverträge abdecken, direkt mit dem Erwerb der Vectron-Kassen über den Fachhandel dazubuchen. Wir haben die Vectron Systems AG im Rahmen eines DCF-Modells bewertet und ein Kursziel in Höhe von 21,15 € ermittelt und vergeben das Rating KAUFEN.

Aktuelle Research-Studie

Original-Research: Rock Tech Lithium Inc. (von Montega AG): Kaufen Rock Tech Lithium Inc.

14. Juni 2021